Gilead Sciences (GILD) AI Stock Analysis

Gilead Sciences

(Six Swiss:GILD)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Strong cash generationExceptionally strong operating and free cash flow provides financial resilience even when reported earnings are weak. This supports continued investment in research and development, funding for launches, debt servicing, and shareholder returns without relying solely on external financing.

Negative Factors

Biktarvy pricing pressureThe planned CMS price reduction creates a material, identifiable pressure on Gilead’s largest HIV product and may also affect other U.S. payer channels. Replacing that revenue will require sustained growth from newer HIV products and other therapeutic areas.

Gilead Sciences (GILD) vs. iShares MSCI Switzerland ETF (EWL)

Market Cap: CHF 211.20B
Dividend Yield: 1.89%
Average Volume (3M): 25
Price to Earnings (P/E): -54.9
Beta (1Y): 0.30
Revenue Growth: 0.32%
EPS Growth: -143.99%
Country: Switzerland
Employees: 17,000
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - General

Gilead Sciences Business Overview & Revenue Model

Company Description

Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to a...

Gilead Sciences Earnings Call Summary

Earnings Call Date:Oct 28, 2026(Q3-2026)|% Change Since:4.89%|Next Earnings Date:Feb 03, 2027

Earnings Call SentimentPositive

The call was strongly positive overall. Gilead reported its strongest base business growth in more than a decade, broad-based product momentum, improved margins, raised revenue and adjusted EPS guidance, significant pipeline progress, and continued diversification across HIV, oncology, inflammation, and cell therapy. These positives outweighed the stated challenges, including the projected $1.5 billion 2028 Biktarvy revenue impact from CMS pricing, cell therapy declines, clinical holds, lower Veklury and HCV sales, and acquisition-related charges.

Positive Updates

Strongest Base Business Growth in More Than a Decade

Third-quarter base business sales rose 16% year-over-year to $8.2 billion, the strongest growth in more than a decade and the highest year-over-year growth since 2015. Growth was driven by Biktarvy, Descovy and Yeztugo in HIV, Trodelvy in metastatic breast cancer, and Livdelzi in PBC. Sequentially, base business sales increased 8%.

Negative Updates

Biktarvy Maximum Fair Price Creates a 2028 Revenue Headwind

CMS set Biktarvy pricing at $2,600 per 30-day supply, an approximate 38% discount from the list price in the Medicare channel. Gilead's preliminary analysis projects an approximately $1.5 billion net impact on Biktarvy revenue in 2028, including Medicare and spillover effects across Medicaid, 340B, and other U.S. payer segments.

Company Guidance

Gilead now expects 2026 base business sales to range between $30.7 billion and $31 billion, total product sales to range between $31 billion and $31.3 billion, HIV sales to grow approximately 12% year-over-year, Yeztugo sales of approximately $1 billion for the full year, cell therapy sales to decline mid-teens percentage year-over-year, Veklury sales of approximately $300 million, acquired IPR&D of approximately $12.9 billion, R&D expenses to increase a mid- to high single-digit percentage on a dollar basis and SG&A expenses to increase by a high single-digit percentage on a dollar basis, an effective tax rate between 220% and 165%, non-GAAP loss per share between $1.20 and $0.85, and, excluding approximately $9.95 per share, non-GAAP diluted EPS of $8.75 to $9.10, raised $0.25 on both ends from illustrative August guidance; for 2028, Gilead expects a total net impact to Biktarvy revenue of approximately $1.5 billion, total HIV revenue to grow compared to 2027, and both total product sales and earnings per share to grow compared to 2027.

Gilead Sciences Risk Analysis

Gilead Sciences disclosed 22 risk factors in its most recent earnings report. Gilead Sciences reported the most risks in the "Tech & Innovation" category.

Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

0 New Risks

Gilead Sciences Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

CH:GILD against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NVS	72Outperform	$298.74B	30.87	24.24%	2.93%	1.64%	-28.72%
JNJ	70Outperform	$657.68B	41.02	19.55%	1.95%	7.81%	-35.95%
PFE	68Neutral	$173.95B	40.52	4.89%	5.61%	-0.21%	-59.71%
BMY	66Neutral	$127.71B	13.94	43.88%	4.00%	4.19%	52.55%
MRK	63Neutral	$368.89B	151.39	5.10%	2.29%	5.16%	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

CH:GILD and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
CH:GILD	Gilead Sciences	139.08	73.03	110.57%
BMY	Bristol-Myers Squibb Company	63.02	19.37	44.39%
JNJ	Johnson & Johnson	270.56	87.82	48.06%
MRK	Merck & Company	148.36	66.89	82.11%
NVS	Novartis AG	161.52	38.91	31.74%
PFE	Pfizer Inc	30.67	7.96	35.07%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Gilead Sciences AI Stock Analysis